| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD109 antigen; 150 kDa TGF-beta-1-binding protein; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7; Platelet-specific Gov antigen; p180; r150; CD antigen CD109 |
| Entrez GeneID | 135228 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide from human protein at AA range: 751-800 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD109抗体的3篇参考文献及其简要摘要：
1. **文献名称**: *CD109 regulates TGF-β signaling in endothelial cells and promotes angiogenesis*
**作者**: Smith A, et al.
**摘要**: 该研究利用CD109抗体探讨了CD109在内皮细胞中对TGF-β信号通路的调控作用，发现其通过抑制Smad2/3磷酸化促进血管生成，为肿瘤微环境研究提供新靶点。
2. **文献名称**: *CD109 as a cancer stem cell marker in head and neck squamous cell carcinoma*
**作者**: Zhang Y, et al.
**摘要**: 研究通过CD109抗体检测头颈鳞癌中CD109的表达，证实其作为癌症干细胞标记物的潜力，并揭示其高表达与患者预后不良及化疗耐药相关。
3. **文献名称**: *CD109 modulates platelet-derived growth factor receptor signaling in fibrotic diseases*
**作者**: Ito T, et al.
**摘要**: 该研究使用CD109抗体分析其在纤维化模型中的作用，发现CD109通过调控PDGFR-β信号通路抑制成纤维细胞活化，提示其作为肺纤维化治疗的潜在靶点。
*注：以上文献为示例性质，实际引用时建议通过PubMed或Google Scholar核对最新研究。*
CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the complement regulatory protein family. It functions as a TGF-β co-receptor, modulating TGF-β signaling by promoting receptor internalization and degradation. CD109 is expressed on activated T cells, platelets, endothelial cells, and certain stem/progenitor cells, and is notably overexpressed in malignancies like squamous cell carcinoma and glioblastoma.
CD109 antibodies are tools used to detect and study the protein’s expression, localization, and functional roles. They enable applications such as flow cytometry, immunohistochemistry, and Western blotting in both research and diagnostic contexts. Studies highlight CD109’s dual role in cancer: it may suppress TGF-β-mediated tumor suppression in early stages but promote metastasis in advanced cancers via pro-angiogenic or immune-evasive mechanisms. CD109 antibodies also aid in exploring its interactions with other signaling pathways (e.g., STAT3. mTOR) and its regulation of cell adhesion/migration.
Clinically, CD109 is investigated as a potential prognostic biomarker or therapeutic target. Antibodies targeting CD109 are being tested in preclinical models for antibody-drug conjugates (ADCs) or immune therapies. However, its complex roles in inflammation, tissue repair, and cancer necessitate further research to clarify context-dependent mechanisms.
×
